AGY.L
Price:
$7.25
Market Cap:
$345.57M
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2004-10-11
Stock Exchange
LSE
Ticker
AGY.L
According to Allergy Therapeutics plc’s latest financial reports and current stock price. The company's current PE Ratio is -7.25. This represents a change of 192.50% compared to the average of -2.48 of the last 4 quarters.
The mean historical PE Ratio of Allergy Therapeutics plc over the last ten years is 10.96K. The current -7.25 PE Ratio has changed -106.61% with respect to the historical average. Over the past ten years (40 quarters), AGY.L's PE Ratio was at its highest in in the December 2015 quarter at 4.10K. The PE Ratio was at its lowest in in the June 2011 quarter at -849.68.
Average
10.96K
Median
-2.27
Minimum
-6103.83
Maximum
109.95K
Discovering the peaks and valleys of Allergy Therapeutics plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.58%
Maximum Annual PE Ratio = 109.95K
Minimum Annual Increase = -218.91%
Minimum Annual PE Ratio = -6103.83
Year | PE Ratio | Change |
---|---|---|
2024 | -4.37 | 2.58% |
2023 | -0.16 | -99.98% |
2022 | -968.54 | -116.66% |
2021 | 5.82K | 336.46% |
2020 | 1.33K | -49.61% |
2019 | 2.64K | -218.91% |
2018 | -2223.80 | -63.57% |
2017 | -6103.83 | 655.77% |
2016 | -807.63 | -100.73% |
2015 | 109.95K | 1.07% |
The current PE Ratio of Allergy Therapeutics plc (AGY.L) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-324.36
5-year avg
1.23K
10-year avg
10.96K
Allergy Therapeutics plc’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Allergy Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Allergy Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Allergy Therapeutics plc's PE Ratio?
How is the PE Ratio calculated for Allergy Therapeutics plc (AGY.L)?
What is the highest PE Ratio for Allergy Therapeutics plc (AGY.L)?
What is the 3-year average PE Ratio for Allergy Therapeutics plc (AGY.L)?
What is the 5-year average PE Ratio for Allergy Therapeutics plc (AGY.L)?
How does the current PE Ratio for Allergy Therapeutics plc (AGY.L) compare to its historical average?